1 of 1
Story summary
- The Institute of Cancer Research (ICR) in London developed a dual genetic test predicting 84% of early relapses in multiple myeloma.
- The study used DNA profiling with RNA gene expression testing to track 135 patients over seven years and found 18.5% relapsed within 18 months after stem cell transplant.
- The Royal Marsden Hospital in London plans to implement MMprofiler, the gene expression profiling test, in early 2026 to improve treatment.
